Trastuzumab rezetecan vs Tucatinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HER2-Positive Breast Cancer

Shared mechanism: HER2 · full HER2-Positive Breast Cancer pipeline

Trastuzumab rezetecan

Marketed by Jiangsu Hengrui Pharmaceuticals and partners

Phase 3 in HER2-Positive Breast Cancerantibody-drug conjugate
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2027 · NCT07416253 (registry estimate)

No aligned efficacy figure on record for this race.

Tucatinib

Marketed by Pfizer and partners

Approved in HER2-Positive Breast Cancersmall molecule
Reliable signal

NCT03975647 · Phase 3 · active, not recruiting

This was a randomized, quadruple-masked, placebo-controlled trial of 466 patients, with progression-free survival as the primary endpoint. The primary comparison reached statistical significance in favor of tucatinib (hazard ratio 0.759, p=0.0163).

Next expected readout: December 2026 · NCT06016387 (registry estimate)

Reported efficacy

Progression-free survival (PFS) by investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (Up to approximately 3 years): HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001. (met)

Result source: NCT05132582

Results for HER2-Positive Breast Cancer

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Trastuzumab rezetecan: no structured comparison results are available for HER2-Positive Breast Cancer.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Tucatinib

PFS 9.5 vs 7.4 placebo months
time to event · months
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
show 7 more results
7.8 vs 5.7 placebo months
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
9.6 vs 7.4 placebo months
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
7.8 vs 5.5 placebo months
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
7.8 vs 5.6 placebo months
NCT02614794 · Phase 2 · combination
7.6 vs 5.4 placebo months
NCT02614794 · Phase 2 · combination
7.5 vs 4.3 placebo months
NCT02614794 · Phase 2 · combination
7.6 vs 4.9 placebo months
NCT02614794 · Phase 2 · combination
ORR 42% (n=188) vs 36.1% (n=191) placebo
responder rate · % of participants
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
show 3 more results
47.3% (n=182) vs 41.1% (n=185) placebo
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
40.7% (n=273) vs 23.4% (n=137) placebo
NCT02614794 · Phase 2 · combination
41.4% (n=280) vs 23% (n=139) placebo
NCT02614794 · Phase 2 · combination
Overall Survival 21.9 vs 17.4 placebo months
time to event · months
NCT02614794 · Phase 2 · combination
show 1 more result
24.7 vs 19.2 placebo months
NCT02614794 · Phase 2 · combination
Duration of Response 8.3 vs 6.3 placebo months
time to event · months
NCT02614794 · Phase 2 · combination
show 1 more result
7 vs 6.9 placebo months
NCT02614794 · Phase 2 · combination
Clinical Benefit 59.8% (n=410) vs 38.1% (n=202) placebo
responder rate · % of participants
NCT02614794 · Phase 2 · combination
show 1 more result
58% (n=410) vs 37.6% (n=202) placebo
NCT02614794 · Phase 2 · combination
Available safety results

Tucatinib

Dropout rate
34.6%
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
show 1 more result
n/a: no completion milestone
NCT02614794 · Phase 2 · combination
Discontinued due to AEs
—
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
show 1 more result
—
NCT02614794 · Phase 2 · combination
Serious AEs
30.3%
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
show 1 more result
30.7%
NCT02614794 · Phase 2 · combination
Most frequent reported AEs
nausea 65.4% (placebo 48.5%)
diarrhoea 56.7% (placebo 26.6%)
fatigue 48.9% (placebo 36.5%)
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
show 1 more result
diarrhoea 81.7% (placebo 53.8%)
palmar-plantar erythrodysaesthesia syndrome 65.6% (placebo 53.3%)
nausea 60.1% (placebo 44.2%)
NCT02614794 · Phase 2 · combination

Breast Cancer

Shared mechanism: HER2 · full Breast Cancer pipeline

Trastuzumab rezetecan

Marketed by Jiangsu Hengrui Pharmaceuticals and partners

Phase 3 in Breast Cancerantibody-drug conjugate
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT05076682 (registry estimate)

No aligned efficacy figure on record for this race.

Tucatinib

Marketed by Pfizer and partners

Approved in Breast Cancersmall molecule
Reliable signal

NCT03975647 · Phase 3 · active, not recruiting

This was a randomized, quadruple-masked, placebo-controlled trial of 466 patients, with progression-free survival as the primary endpoint. The primary comparison reached statistical significance in favor of tucatinib (hazard ratio 0.759, p=0.0163).

Next expected readout: November 2026 · NCT05323955 (registry estimate)

Reported efficacy

Progression-free survival (PFS) by investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (Up to approximately 3 years): HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001. (met)

Result source: NCT05132582

Results for Breast Cancer

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Trastuzumab rezetecan: no structured comparison results are available for Breast Cancer.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Tucatinib

PFS 9.5 vs 7.4 placebo months
time to event · months
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
show 7 more results
7.8 vs 5.7 placebo months
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
9.6 vs 7.4 placebo months
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
7.8 vs 5.5 placebo months
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
7.8 vs 5.6 placebo months
NCT02614794 · Phase 2 · combination
7.6 vs 5.4 placebo months
NCT02614794 · Phase 2 · combination
7.5 vs 4.3 placebo months
NCT02614794 · Phase 2 · combination
7.6 vs 4.9 placebo months
NCT02614794 · Phase 2 · combination
ORR 42% (n=188) vs 36.1% (n=191) placebo
responder rate · % of participants
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
show 3 more results
47.3% (n=182) vs 41.1% (n=185) placebo
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
40.7% (n=273) vs 23.4% (n=137) placebo
NCT02614794 · Phase 2 · combination
41.4% (n=280) vs 23% (n=139) placebo
NCT02614794 · Phase 2 · combination
Overall Survival 21.9 vs 17.4 placebo months
time to event · months
NCT02614794 · Phase 2 · combination
show 1 more result
24.7 vs 19.2 placebo months
NCT02614794 · Phase 2 · combination
Duration of Response 8.3 vs 6.3 placebo months
time to event · months
NCT02614794 · Phase 2 · combination
show 1 more result
7 vs 6.9 placebo months
NCT02614794 · Phase 2 · combination
Clinical Benefit 59.8% (n=410) vs 38.1% (n=202) placebo
responder rate · % of participants
NCT02614794 · Phase 2 · combination
show 1 more result
58% (n=410) vs 37.6% (n=202) placebo
NCT02614794 · Phase 2 · combination
Available safety results

Tucatinib

Dropout rate
34.6%
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
show 1 more result
n/a: no completion milestone
NCT02614794 · Phase 2 · combination
Discontinued due to AEs
—
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
show 1 more result
—
NCT02614794 · Phase 2 · combination
Serious AEs
30.3%
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
show 1 more result
30.7%
NCT02614794 · Phase 2 · combination
Most frequent reported AEs
nausea 65.4% (placebo 48.5%)
diarrhoea 56.7% (placebo 26.6%)
fatigue 48.9% (placebo 36.5%)
NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3
show 1 more result
diarrhoea 81.7% (placebo 53.8%)
palmar-plantar erythrodysaesthesia syndrome 65.6% (placebo 53.3%)
nausea 60.1% (placebo 44.2%)
NCT02614794 · Phase 2 · combination

Colorectal Cancer

Shared mechanism: HER2 · full Colorectal Cancer pipeline

Trastuzumab rezetecan

Marketed by Jiangsu Hengrui Pharmaceuticals and partners

Phase 3 in Colorectal Cancerantibody-drug conjugate
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: May 2028 · NCT07796763 (registry estimate)

No aligned efficacy figure on record for this race.

Tucatinib

Marketed by Pfizer and partners

Approved in Colorectal Cancersmall molecule
Partial signal

NCT03043313 · Phase 2 · completed

The study included a randomized cohort and an objective tumor-response endpoint assessed by blinded independent central review, but treatment assignment was open-label and the primary analysis pooled a non-randomized cohort with the randomized combination-therapy cohort rather than testing a prespecified arm-to-arm comparison. The reported primary response result was therefore descriptive rather than a statistically tested comparison, supporting moderate rather than strong evidence.

Next expected readout: December 2026 · NCT05382364 (registry estimate)

Reported efficacy

Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5) (not_applicable)

Result source: NCT03043313

Results for Colorectal Cancer

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Trastuzumab rezetecan: no structured comparison results are available for Colorectal Cancer.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Tucatinib
Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5) NCT03043313 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Trastuzumab rezetecan's landscape · Tucatinib's landscape